IDT Shares IDT Australia Limited
ASX · ASXLast in our picks 2026-09-29 — not in the current list; analysis below is from that screen
Small-cap biotech manufacturing and development exposure with selective catalyst potential.
Signal breakdown
- ▸Potential catalysts, but liquidity and scale remain limited.
- ▸Above 50-day MA (+2.93%)
- ▸Above 200-day MA — long-term uptrend
- ▸Volume 2.17× average — accumulation
Is IDT a buy right now?
Trend: IDT is trading above the 50-day average (+0.00%), RSI 53 — neutral momentum, with a 3-month return of +14.29%.
Valuation & quality: IDT Australia Limited trades on forward P/E 4.0, PEG 2.75, price-to-book 0.89; fundamentals show net margin -13.3%, return on equity -13.3%, revenue growth 14.8% year on year.
Our screen: BUY (score 3) — Small-cap biotech manufacturing and development exposure with selective catalyst potential.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -20.00% | +0.00% | +0.00% | -25.00% | +33.30% | +25.00% | +0.00% | -20.00% |
Fundamentals
Technical signals
About IDT Australia Limited
IDT Australia Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (API) and finished dose forms (FDF) products in Australia, Asia, Europe, and the United States.
Sector: Healthcare · Industry: Drug Manufacturers - Specialty & Generic · Australia · Website
Related Biotech picks
Browse: all ASX stocks · Biotech picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.